New Data on Ropeginterferon Alfa-2b to Be Featured at EHA2022
Presentations to illustrate long-term results from the PROUD/CONTINUATION studies as well as new insights on ropeginterferon alfa-2b in polycythemia vera (PV) patients in Japan TAIPEI–(BUSINESS WIRE)–PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced a series of … [Read more…]